Samuel Agresta

Samuel Agresta is Chief Medical Officer at OnKure Therapeutics, Inc. since 2024.
Former positions include Senior Medical Director at Genentech, Inc. from 2007 to 2010; Senior Medical Director at Merrimack Pharmaceuticals, Inc. from 2010 to 2011; Director at Infinity Pharmaceuticals, Inc. from 2019 to 2023; Associate Medical Director at H.
Lee Moffitt Cancer Center & Research Institute, Inc. from 2004 to 2010; Vice President & Head-Clinical Development at Agios Pharmaceuticals, Inc. from 2011 to 2018; and Chief Medical Officer at Foghorn Therapeutics, Inc. from 2019 to 2023.
Education includes graduate studies at the University of South Florida, an undergraduate degree from Georgetown University in 1994, a doctorate from Tulane University School of Medicine, and graduate studies at Tulane University School of Public Health & Tropical Medicine.